top of page
youtube cover2.png


January 3, 2023

Olaris Announces Appointment of Jowin Jestine as Data Engineer

Olaris, Inc. announced today the appointment of Jowin Jestine as a Data Engineer. Jestine has a Bachelors degree in Computer Science and a Masters in Business Analytics and Program Management.

November 1, 2022

Olaris Featured in Microsoft News Article on Microsoft for Startups

Olaris was featured in an article by Microsoft News on the experience of CEO Dr. Elizabeth O'Day with the Founders Hub, part of the Microsoft for Startups program. The article highlights the support systems available through Microsoft for Startups as well as the entrepreneurial journey faced by a female CEO in the biotech industry.

October 13, 2022

Olaris CEO Dr. Liz O'Day Featured by Boston Business Journal as a 2022 Mover and Shaker

Olaris CEO Dr. Elizabeth O'Day was featured in an article by the Boston Business Journal as a 40 under 40 alumni Mover and Shaker, honoring the company's progress since her selection as a 40 under 40 recipient in 2020.

September 12, 2022

Olaris Announces Appointment of Dr. Jurre Kamphorst as Vice President of MS Technology & Biomarkers

Olaris, Inc. announced today the appointment of Dr. Jurre Kamphorst as Vice President of Mass Spectrometry Technology and Biomarkers. Dr. Kamphorst has a Ph.D. in Bioanalytical Sciences from Leiden University in the Netherlands and was most recently the Director of Clinical Metaoblism and Biomarkers at Rheos Medicines.

June 1, 2022

Olaris, Inc. to present at American Transplant Congress 2022 Meeting

Olaris, Inc., a precision medicine company leveraging metabolomics and machine learning for the discovery and development of its myOLARIS™ diagnostics products, which aim to optimize treatments and outcomes for individual patients, is pleased to announce that the company’s study on the application of the myOLARIS-KTdx kidney transplant graft status score to transplant recipients has been selected for a poster presentation on June 6th  at the upcoming American Transplant Congress (ATC) 2022 Annual Meeting, to be held June 4th-8th in Boston, Massachusetts. To view the poster presentation, visit .

May 6, 2022

Olaris CEO Selected As 2022 EY Entrepreneur of the Year® New England Finalist

We are thrilled to announce that Olaris Founder and CEO Dr. Liz O'Day has been named a New England finalist for the EY Entrepreneur of the Year award. EY Entrepreneur Of The Year is one of the preeminent competitive business wards for entrepreneurs and leaders of high-growth companies.

April 4, 2022

Olaris Data Scientist Chen Dong Featured in Mass Life Sciences Center Success Stories

Olaris Data Scientist Chen Dong was featured in the Success Stories page on the website of the Massachusetts Life Sciences Center (MLSC). Chen began as an MLSC-sponsored intern at Olaris in 2019, and his hard work has helped to drive Olaris' success, most recently with a publication on metabolite-based diagnostics for Parkinson's disease in men with LRRK2 mutations.

March 15, 2022

Olaris CEO Dr. Liz O'Day Serves as Visiting Scientist at National Heart, Lung, and Blood Institute

Olaris Founder and CEO Dr. Liz O'Day is serving today as a virtual visiting scientist at the National Heart, Lung, and Blood Institute Biochemistry and Biophysics Center. Dr. O'Day will give a presentation on how machine learning and artificial intelligence can be combined with NMR and metabolomics to better understand the biology underlying Parkinson's Disease.

March 8, 2022

Olaris Announces Appointment of Dr. Keri Sheehan as Director of Communications and Project Management

Olaris, Inc. announced today the appointment of Dr. Keri Sheehan as Director of Communications and Project Management. Dr. Sheehan holds a Ph.D. in Immunology from University of Pennsylvania, where she worked on the molecular dynamics of the cytoskeleton in natural killer cells, and completed postdoctoral fellowships at Harvard Medical School and UMass Chan Medical School. She has over 5 years of experience in improving research communications and scientific journal processes.

March 4, 2022

Olaris CEO Dr. Liz O'Day Presents at Horasis USA Meeting 2022

Olaris Founder and CEO Dr. Liz O'Day presents today at the Horasis USA Meeting in a panel on female entrepreneurs in tech.

February 28, 2022

Olaris CEO Dr. Liz O'Day Serves as Mentor for Boston Business Journal BizWomen Mentoring Monday

Olaris Founder and CEO Dr. Liz O'Day served as a mentor today in the 9th annual Boston Business Journal Mentoring Monday program. The one-of-a-kind virtual event brought together women in business for a networking and fun in a fast-paced coaching atmosphere. The Boston event featured keynote speaker Michelle Wu, 3 panel sessions, and breakout mentoring sessions.

February 3, 2022

Olaris Announces Appointment of Dr. Jifang Zhao as Senior Data Scientist

Olaris, Inc. announced today the appointment of Dr. Jifang Zhao as a Senior Data Scientist on the Data Science team. Jifang has years of expertise in statistics and machine learning and holds a Ph.D. and a Masters in Statistics from Virginia Commonwealth University, where he developed novel methods for processing large-scale, high-dimensional data from neuroimaging.

October 11, 2021

Olaris Attending HLTH 2021 in Boston with Microsoft for Startups

Find us at HLTH 2021 in Boston to connect and learn more about our to our pioneering metabolomics platform and machine learning algorithms that produce Biomarkers of Response which can differentiate drug responders from non-responders and ensure optimal treament. We are building our BoR pipeline across oncology, transplant, and neurodegeneration. Contact to set up a time.

October 8, 2021

Women In Biopharma: Seven women in life sciences weigh in on the challenges facing the industry

This week, the Business Journal featured a handful of Boston-area women in the industry, both established leaders as well as those who are just breaking onto the scene, at its Women Who Lead in Life Sciences event. In the following pages, they discuss their careers, the challenges facing their industry and what needs to be done to promote women in the male-dominated field.

August 2, 2021

Olaris CEO Joins New AACR Working Group on Cancer Evolution

Why is cancer so hard to treat? How can we overcome resistance? Cancer is an everchanging disease-and many of the greatest treatment challenges are driven by clonal evolution. We must adapt to keep up!

In a great step, the AACR has formed the new Cancer Evolution working group, with Olaris CEO Dr. Liz O'Day on the Steering Committee. Co-chaired by Frank Laukien, CEO of Bruker, and Charles Swanton of the Francis Crick and UCL Cancer Institutes, this group of experts will translate cutting-edge research into new diagnostic, therapeutic, and prevention strategies.

A new way of treating cancer is coming, and biomarkers will be the guide!

July 13, 2021

Microsoft's Tom Davis: Dr. Liz O'Day brings scientific rigor to the business of precision medicine

From the laboratory to the boardroom, Tom Davis discovers how Dr. Liz O’Day applied her science career to founding biotech startup Olaris in the latest "Meet The Innovators" series.

July 9, 2021

Olaris CEO Recognized as Innovative Female Founder in Healthcare by Microsoft for Startups

When an estimated 7% of all health & life science startups are started by women, these five female founders are leading some of the most innovative companies in transforming healthcare services. Read more from Sally Ann Frank on The Record  about how their startup ideas led to fast-moving businesses. 

June 10, 2021

Olaris CEO Selected As 2021 Entrepreneur of the Year New England Finalist

We are honored to have Dr. Liz O'Day recognized among so many unstoppable business leaders in New England as one of the Finalists for EY Entrepreneur of The Year! For 35 years, the award has recognized game-changing entrepreneurs - those who have ushered in innovation throughout their careers and who are disrupting industries with each step they take. 

June 3, 2021

Olaris BoR Technology on C-Sessions with Randall Broad

 Olaris CEO and Founder Dr. Liz O'Day had the opportunity to share the origin of BoR technology with C-sessions and describe how our BoRs can be used as a tool to determine which treatment is best for each patient- even before they start therapy. Listen below to learn how Olaris BoRs in oncology can empower patients and providers to be confident in their treatment.

May 2, 2021

Boston Business Journal: Olaris founder Liz O'Day works to make personalized medicine a reality

Liz O'Day has founded a for-profit biotech company, a nonprofit organization and is working hard to help the world return not only to 'some version of normal but hopefully even better.'

March 31, 2021

Dr. Elizabeth O'Day Selected to Join the Biological Magnetic Resonance Bank Advisory Board

Dr. O'Day is thrilled to join the BMRB advisory board to help expand the internationally renowned repository for biomolecular NMR data. Dr. O'Day will serve as a metabolomics and biotech advisor as BRMB develops additional content and tools to serve users of the repository. 

March 3, 2021

Olaris CEO Featured on Catalyst Health Innovation Summit Panel

Dr. O'Day was joined by industry experts and thought leaders Joshua Weiner, Healthcare Strategy at Facebook, and Dr. Martin-Immanuel Bittner, CEO of Arctoris, to discuss biotech innovations during the pandemic and to share their insights on the future of healthcare during their panel at Cataylst HIF 2021.

January 20, 2021

Dr. Elizabeth O'Day, Olaris CEO, and Dr. Mike Pellini, Managing Director of Section 32 speak on BC panel

Dr. Elizabeth O'Day and Dr. Mike Pellini discuss how far biotechnology has come in the last decade and share their insights on how robust diagnostics will usher in the future of precision medicine. Watch their panel in the recap below.

November 13, 2020

Scientific American Top 10 Emerging Tech of 2020: Olaris CEO Discusses Microneedles

Read Olaris CEO Dr. Elizabeth O'Day's article on how microneedles could enable painless injections and blood draws in Scientific Americans Top 10 Emerging Technologies of 2020. 

November 3, 2020

Olaris CEO Featured in Authority Magazine's Female Disruptors Series

"My baseline for whether disruption is ‘good’ is thinking about whether the change in the industry will have a genuinely positive impact on people’s lives. Of course, this is a subjective measure, but in the case of Olaris, you can make the strong argument that our platform for determining which patients will benefit from a specific therapy will improve the lives of millions." - Dr. Elizabeth O'Day as interviewed in Authority Magazine's Female Disruptors series aimed to feature women bringing radical change to their industry. 

October 30, 2020

Olaris Presents At BU Questrom's Annual Health and Life Sciences Conference

Dr. Elizabeth O'Day discussed how Olaris leverages metabolomics and machine learning through our Biomarkers of Response platform to determine the most effective therapies for patients - providing the right drug, to the right patient, at the right time.

October 26, 2020

Olaris Honored to Recieve BostInno's 50 on Fire 2020 Award

Olaris was selected for BostInno's 50 on Fire award for our Biomarkers of Response platform to determine whether a patient will respond to certain drugs or treatments for certain types of diseases. Our technology was recognized by STAT for developing biomarker-based tests over the past year for metastatic breast cancer, metastatic gastrointestinal stromal tumors, Parkinson’s Disease and for immunosuppressive drugs given before a kidney transplant.

October 20, 2020

Olaris Featured in Node by Slush Event with Astrazeneca

Olaris joined Astrazeneca on October 20th for the first of two digital engagement events with Slush, focusing on ‘Healthcare of the future – a roadmap towards collaborative value creation’ to present our unique Biomarkers of Response platform. 

October 16, 2020

Olaris Presents at Groundbreaking Cancer & Evolution Symposium

Dr. Elizabeth O'Day joined influential scientists in cancer biology and evolutionary biology, including Azra Raza, George Church, Adelene Perkins, Frank Laukien, and Denis Noble, at the first meeting of the Cancer and Evolution Symposium to present the Olaris BoR platform for assessing breast cancer patient response to CDK4/6 inhibitors to improve outcomes.


View Dr. O'Day's talk below.  

September 29, 2020

Olaris CEO Panelist Speaker at The Digital Clinical Biomarkers & World CDx Summit

Dr. Elizabeth O'Day participated in an excellent panel discussion on Women and Diversity in Precision Medicine with Dr. Maria C.M. Orr (Head of Precision Medicine for Biopharmaceuticals at Astrazeneca) and Nina Green (VP and GM of Companion Diagnostics at Agilent Technologies) at the Clinical Biomarkers and World CDx Summit in September.

Increasing diversity in precision medicine must be deliberate, and the "Yes And, No But" challenge can do just that. When accepting an opportunity, suggest a colleague or individual who you think would also benefit from and contribute to the experience but may not have been offered the opportunity. If you are unable to accept, suggest someone who is less likely to be invited to go in your place!

September 23, 2020

COO Leslie Hoyt Speaker for HBA Women's Leadership Panel

Olaris CCO and COO Leslie Hoyt spoke at the Healthcare Businesswomen's Association's event "The Women’s Leadership Gap: Climbing Beyond the Broken Rung in the Career Ladder." Leslie was joined by four highly accomplished women in the science and pharmaceutical space who have climbed beyond the ‘broken rung’ in their career ladders and excelled into leadership positions, including Dr. Alita Miller (VP of Biosciences Entasis Therapeutics), Dr. Shruta Rege (Head of  Regulatory Affairs at Entasis), Dr. Nerissa Kreher (CMO of Tiburio Therapeutics) and Deb Tatton (Senior VP of GCO at Parexel). 

September 23, 2020

Olaris CEO Selected for Boston Business Journals 40 under 40

Dr. Elizabeth O’Day was selected for the Boston Business Journals 40 under 40 award which highlights the best and brightest professionals in the Greater Boston area.

September 1, 2020

In Her Own Words: Olaris founder Dr. Elizabeth O’Day’s biopharma company was at the crossroads of performance and pandemic

Dr. Elizabeth O’Day’s Olaris team had developed a platform that could help patients suffering from breast cancer and Parkinson’s as well as other diseases get the right drugs at the right time. And then Covid-19 hit. Read more in The Business Journals feature.

August 7, 2020

Check out our latest article on personalized medicine in the Middle East and North Africa!

Biomarkers are the fuel for precision medicine and prevention. But what happens to populations for which biomarker data is lacking? CEO and Founder Dr. Elizabeth O'Day co-authored a piece through the WEF on the potential for genomic and lifestyle studies to make for a healthier future in the Middle East and North Africa (MENA).

July 23, 2020

"The Death of Disease?"; Panel Featuring Olaris CEO Dr. Elizabeth O'Day

This summer, 32,000 people from around the world tuned into Collision, North America's fastest-growing tech conference. Dr. O'Day spoke on "The Death of Disease?" panel, where she discussed the prospects of a disease-free world. 

June 25, 2020

Inspiration on the Personalized Medicine Podcast

The latest episode of the Personalized Medicine Podcast features CEO and Founder Dr. Liz O'Day discussing everything from science to comic books to business to even detailing the joys and frustrations of a western blot   Available via your favorite podcast platform! 


Apple Podcasts

Pocket Casts



Google Podcasts:

June 24, 2020

Passion and Purpose. Fireside Chat with StartUp Grind

Purpose & Passion. Check out Startup Grind's fireside chat with CEO and Founder Dr. Elizabeth O'Day on what is like to transition from academia to industry and start a company. Thank you to sponsors Google for Startups,  SVB Financial Group and Brex

June 9, 2020

Xconomy Xcelerating Life Science Highlight Podcast Featuring Olaris CEO Dr. Elizabeth O'Day

The highlight reel is out from Xconomy's Xcelerating Life Sciences event. Tune in for a recap and check out minutes 18:45-21:00 to hear Olaris CEO Dr. Elizabeth O'Day discuss why the world needs precision medicine now more than ever in the COVID-19 era.

May 28, 2020

World Economic Forum releases final Vision Statement for Precision Medicine

Over the past year, Olaris CEO, Dr. Liz O'Day , has served on the World Economic Forum's Global Precision Medicine Council to unlock precision medicine in healthcare for all. Dr. O'Day led the task force focusing on Access and Fair Pricing. Today the World Economic Forum released the final Vision Statement for Precision Medicine! Find WEF's recommendations for advancing precision medicine globally here.

May 22, 2020

Olaris CEO, Dr. Elizabeth O'Day, contributes to USP's Trust or Consequences 2040 Report

Just weeks before COVID19 made headlines, Olaris CEO, Dr. Liz O'Day, collaborated with 100+ global experts to explore the future of medicine & healthcare. The project was a joint effort of U.S. Pharmacopeia and SupermindsMIT. A recurring theme between now and 2040 was the increasing frequency of global crises, like COVID-19. Read more in the full report, Trust or Consequences 2040, here.

bottom of page